论文部分内容阅读
目的:观察纤溶酶治疗急性脑梗死(ACI)的疗效和不良反应。方法:将82例急性脑梗死患者按住院顺序随机分为对照组和治疗组进行对比研究,对照组采用常规内科治疗,治疗组在此基础上加用纤溶酶静滴,1次/d,连用10天;分别对两组治疗前、治疗后11天神经功能缺损评分及临床疗效进行评估和血液流变学比较,观察药物不良反应。结果:两组治疗后的神经功能缺损较治疗前均有显著改善(P<0.01),治疗组与对照组比较有显著性差异(P<0.01),治疗后临床疗效评价治疗组总有效率92.8%,与对照组62.5%比较有明显差异(P<0.01);两组血液流变学检查结果,治疗组明显要优于对照组,有统计学意义(P<0.05)。两组均未发现药物不良反应和毒副作用。结论:纤溶酶作为治疗急性脑梗死,安全有效且价格适中,值得医院推广应用。
Objective: To observe the efficacy and adverse reactions of plasmin in the treatment of acute cerebral infarction (ACI). Methods: A total of 82 patients with acute cerebral infarction were randomly divided into control group and treatment group according to the order of hospitalization. The control group was treated by routine medical treatment. On the basis of this group, the patients in the treatment group received intravenous infusion of plasmin, once a day, For 10 days. The neurological deficit score, clinical curative effect and blood rheology of two groups before treatment and 11 days after treatment were compared respectively to observe adverse drug reactions. Results: The neurological deficits in both groups were significantly improved after treatment (P <0.01), and there was significant difference between the two groups (P <0.01). After treatment, the total effective rate of the treatment group was 92.8 %, Compared with 62.5% in the control group (P <0.01). The results of hemorheology in the two groups were significantly better than those in the control group (P <0.05). No adverse drug reactions and side effects were found in both groups. Conclusion: Plasmin as a safe treatment of acute cerebral infarction, safe and effective and affordable, it is worth promoting the application of the hospital.